Skip to content
Medical Health Aged Care

MicroVention Rebrands to Terumo Neuro – Reflects Expanded Focus and Strategic Growth

Terumo Neuro 2 mins read
ALISO VIEJO, Calif.--BUSINESS WIRE--

MicroVention, Inc., a global leader in neurovascular innovation and a wholly owned subsidiary of Terumo Corporation, today announced its official rebranding to Terumo Neuro, effective immediately. This name change signifies a new chapter in the company’s evolution while maintaining its unwavering commitment to the creation and commercialization of groundbreaking innovations in neurovascular care.

Founded in 1997 and acquired by Terumo Corporation in 2006, MicroVention has been at the forefront of developing technologies that support neurovascular surgeons in preserving and restoring brain health. As Terumo Neuro, the company is poised to continue its legacy of innovation with an enhanced focus on driving impactful growth and leveraging Terumo’s global resources and reputation.

Carsten Schroeder, President and CEO of Terumo Neuro, commented on the rebranding: "This transformation reflects our growth as a company and Terumo's confidence in our future. For eighteen years, we have maintained independent branding as MicroVention, and now, as Terumo Neuro, we’re combining the best of MicroVention with the full strength and support of the Terumo family. Our culture, speed of innovation, focus on game-changing technologies, and close collaboration with physicians will remain unchanged."

He continued, "What will evolve is a deeper partnership with Terumo, a new visual brand, and a more defined brand identity under our new name and slogan, ‘Terumo Neuro: Game-changing Impact.’ Our strategy is expanding beyond our core focus on hemorrhagic and ischemic stroke and access solutions to encompass the neurovascular patient care continuum."

As Terumo Neuro, the company will continue its close collaboration with leading physicians worldwide, translating clinical insights into technologies that enhance patient outcomes. Schroeder emphasized that the company’s DNA remains rooted in innovation for ischemic stroke, hemorrhagic stroke, and access, while expanding into broader areas of neurovascular care.

About Terumo Neuro (Formerly MicroVention, Inc.)

We are in business to create and deliver Game-changing Impact™—innovations that redefine what is possible in neuroendovascular treatment to meaningfully advance both physician practice and patient outcomes. Founded in 1997 as MicroVention and acquired by Terumo Corporation in 2006, Terumo Neuro offers more than thirty products for the treatment of cerebral aneurysms, ischemic stroke, carotid artery disease, and neurovascular malformations. Headquartered in California, Terumo Neuro products are sold in more than seventy countries through a direct sales organization as well as strategic distribution partnerships. Manufacturing facilities are in Aliso Viejo, California, and San José, Costa Rica. For more information on Terumo Neuro, please visit www.terumoneuro.com.

About Terumo Corporation

Terumo (TSE:4543) is a global leader in medical technology and has been committed to "Contributing to Society through Healthcare" for one hundred years. Based in Tokyo and operating globally, Terumo employs more than 30,000 associates worldwide to provide innovative medical solutions in more than 160 countries and regions. The company started as a Japanese thermometer manufacturer and has been supporting healthcare ever since. Now, its extensive business portfolio ranges from vascular intervention and cardio-surgical solutions, blood transfusion and cell therapy technology, to medical products essential for daily clinical practice. Terumo will further strive to be of value to patients, medical professionals, and society at large.


Contact details:

Media Contact:
Christine McCullough
Global Corporate Communications
Terumo Neuro
+ 1 714 206 9800
christine.mccullough@microvention.com

Media

More from this category

  • Medical Health Aged Care, Research Development
  • 17/02/2025
  • 15:07
Australia New Zealand Gynaecological Oncology Group (ANZGOG)

ANZGOG Announces Keynote Speaker for 2025 Annual Scientific Meeting: A/Professor Carien Creutzberg

The Australia New ZealandGynaecological Oncology Group (ANZGOG) is pleased to welcome internationally renowned Radiation Oncologist Professor Carien Creutzberg as a keynote speaker at the…

  • Contains:
  • Medical Health Aged Care
  • 17/02/2025
  • 11:51
Monash University

Monash Expert: Landmark approval of weight loss drug for heart disease

For the first time in Australia, a weight loss drug has been approved to also treat cardiovascular disease in overweight and obese patients. The Therapeutic Goods Administration (TGA) has granted approval for semaglutide 2.4 mg (sold as Wegovy) to be used as a complementary therapy for reducing major adverse cardiovascular events such as cardiovascular death, non-fatal myocardial infarction (heart attack), or non-fatal stroke. The approval follows findings from the SELECT trial, an international study involving more than 17,000 participants across 41 countries, including Australia. Results published in late 2023 showed that Wegovy reduced cardiovascular events by 20 percent in people…

  • Medical Health Aged Care
  • 17/02/2025
  • 10:11
Smith & Nephew UK Ltd

Smith+Nephew steps forward with innovative Sports Medicine foot & ankle repair solutions in Australia and New Zealand

First in market to offer Adjustable Tensioning Technology* for insertional Achilles reconstruction and lateral ankle instability repair*After anchor insertionSmith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces the launch of a comprehensive foot & ankle repair portfolio in Australia and New Zealand (ANZ) with proprietary adjustable tensioning technology. The ULTRABRIDGE◊ Adjustable Achilles Reconstruction and ULTRABRACE◊ Adjustable Ankle Instability Techniques are changing the way foot & ankle surgeons perform these repairs by allowing them to refine and optimise suture tension after anchor insertion.The ability to adjust tension for specific patients allows the surgeon to give the precise amount of range-of-motion…

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.